Completed PHASE2 INTERVENTIONAL 2-arm NCT00868439

Evaluation of Patiromer in Heart Failure Patients (PEARL-HF)

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients

Sponsor: Medpace, Inc.

Conditions Heart Failure Hyperkalemia

Interventions patiromer placebo

Updated 8 times since 2017 Last updated: May 10, 2021 Started: Apr 30, 2009 Primary completion: Nov 30, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00868439, this PHASE2 trial focuses on Heart Failure and Hyperkalemia and remains completed. Sponsored by Medpace, Inc., it has been updated 8 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Sep 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medpace, Inc.
Relypsa, Inc.

Data source: Vifor Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barnaul, Russia , Brno, Czechia , Buffalo, United States , Columbus, United States , Dallas, United States , Dnipropetrovsk, Ukraine , Göttingen, Germany , Heidelberg, Germany , Kemerovo, Russia , Kharkiv, Ukraine and 12 more locations